Contrary to common belief, low biomarker testing rates (30-60%) are not just a community oncology problem; even academic medical centers are "guilty" of failing to test all eligible GI cancer patients. This highlights a systemic challenge in implementing personalized medicine, requiring proactive strategies at all levels of care.

Despite patient interest and marketing, clinical experts are cautious about routine ctDNA use in endometrial cancer. They struggle with interpreting results, worrying that a positive test could lead to unnecessary anxiety and premature or excessive treatment without clear evidence of benefit.

Dr. Deb Schrag suggests the main challenge for new molecular cancer screening technologies is not invention, but implementation. The critical task will be deploying these tools at a population scale and effectively managing the logistical challenge of distinguishing true positives from false alarms.

To avoid the inefficiency of re-requesting tests, some hospital labs now run a full panel of biomarkers (MMR, p53, HER2) on all endometrial cancer cases upfront. This operational decision standardizes the process, even if not every marker is immediately relevant for all histologies, preventing downstream delays and extra work for pathologists.

Clinicians are struggling to implement the new FIGO 2023 molecular staging for endometrial cancer. While prognostically significant, it reclassifies patients (e.g., from Stage 1 to 2C) without clear, validated evidence on how to alter treatment based on the new stage. This gap between staging and evidence-based action creates clinical uncertainty.

Beyond clinical validation, the adoption of novel biomarkers like microRNA is hindered by practical lab issues. Disagreements over sample type (serum vs. plasma), establishing universal cutoffs, and achieving high concordance between different testing centers are critical, non-clinical hurdles that must be overcome for widespread clinical use.

Establishing a multi-disciplinary molecular tumour board helps operationalize biomarker strategies. This collaborative body, including oncologists and surgeons, not only interprets complex molecular data for trial matching but also collectively advocates for health insurance reimbursement for necessary tests, addressing a key practical barrier.

Despite mutation testing being a critical first step for effective treatment planning in gastrointestinal stromal tumors (GIST), a significant number of patients in the United States still do not receive this essential diagnostic. This highlights a major gap between established best practices and real-world clinical application.

Inconsistent methods for assessing biomarkers like PD-L1 (CPS vs. TAP scoring), p53 (IHC vs. sequencing), and HRR (different panels) across major clinical trials make it difficult to compare results and identify a reliable predictive marker for endometrial cancer.